Literature DB >> 23727206

Aggregate plaque volume by coronary computed tomography angiography is superior and incremental to luminal narrowing for diagnosis of ischemic lesions of intermediate stenosis severity.

Ryo Nakazato1, Aryeh Shalev, Joon-Hyung Doh, Bon-Kwon Koo, Heidi Gransar, Millie J Gomez, Jonathon Leipsic, Hyung-Bok Park, Daniel S Berman, James K Min.   

Abstract

OBJECTIVES: This study examined the performance of percent aggregate plaque volume (%APV), which represents cumulative plaque volume as a function of total vessel volume, by coronary computed tomography angiography (CTA) for identification of ischemic lesions of intermediate stenosis severity.
BACKGROUND: Coronary lesions of intermediate stenosis demonstrate significant rates of ischemia. Coronary CTA enables quantification of luminal narrowing and %APV.
METHODS: We identified 58 patients with intermediate lesions (30% to 69% diameter stenosis) who underwent invasive angiography and fractional flow reserve. Coronary CTA measures included diameter stenosis, area stenosis, minimal lumen diameter (MLD), minimal lumen area (MLA) and %APV. %APV was defined as the sum of plaque volume divided by the sum of vessel volume from the ostium to the distal portion of the lesion. Fractional flow reserve ≤ 0.80 was considered diagnostic of lesion-specific ischemia. Area under the receiver operating characteristic curve and net reclassification improvement (NRI) were also evaluated.
RESULTS: Twenty-two of 58 lesions (38%) caused ischemia. Compared with nonischemic lesions, ischemic lesions had smaller MLD (1.3 vs. 1.7 mm, p = 0.01), smaller MLA (2.5 vs. 3.8 mm(2), p = 0.01), and greater %APV (48.9% vs. 39.3%, p < 0.0001). Area under the receiver operating characteristic curve was highest for %APV (0.85) compared with diameter stenosis (0.68), area stenosis (0.66), MLD (0.75), or MLA (0.78). Addition of %APV to other measures showed significant reclassification over diameter stenosis (NRI 0.77, p < 0.001), area stenosis (NRI 0.63, p = 0.002), MLD (NRI 0.62, p = 0.001), and MLA (NRI 0.43, p = 0.01).
CONCLUSIONS: Compared with diameter stenosis, area stenosis, MLD, and MLA, %APV by coronary CTA improves identification, discrimination, and reclassification of ischemic lesions of intermediate stenosis severity.
Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AUC; CAD; CI; CT; CTA; FFR; ICA; ICC; MLA; MLD; NRI; OR; area under the receiver operating characteristic curve; computed tomography; computed tomography angiography; confidence interval; coronary artery disease; coronary computed tomography angiography; coronary plaque; fractional flow reserve; intraclass correlation coefficients; invasive coronary angiography; minimal lumen area; minimal lumen diameter; myocardial ischemia; net reclassification improvement; odds ratio

Mesh:

Year:  2013        PMID: 23727206     DOI: 10.1016/j.jacc.2013.04.062

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  46 in total

1.  Optimal boundary detection method and window settings for coronary atherosclerotic plaque volume analysis in coronary computed tomography angiography: comparison with intravascular ultrasound.

Authors:  Ran Heo; Hyung-Bok Park; Byoung Kwon Lee; Sanghoon Shin; Reza Arsanjani; James K Min; Hyuk-Jae Chang
Journal:  Eur Radiol       Date:  2015-12-02       Impact factor: 5.315

Review 2.  Missense mutations resulting in type 1 lissencephaly.

Authors:  O Reiner; F M Coquelle
Journal:  Cell Mol Life Sci       Date:  2005-02       Impact factor: 9.261

Review 3.  A review of serial coronary computed tomography angiography (CTA) to assess plaque progression and therapeutic effect of anti-atherosclerotic drugs.

Authors:  Jana Taron; Saeyun Lee; John Aluru; Udo Hoffmann; Michael T Lu
Journal:  Int J Cardiovasc Imaging       Date:  2020-02-19       Impact factor: 2.357

4.  Association of coronary plaque burden with fractional flow reserve: should we keep attempting to derive physiology from anatomy?

Authors:  Thura T Abd; Richard T George
Journal:  Cardiovasc Diagn Ther       Date:  2015-02

5.  Computed tomography quantification of coronary plaque volume may provide further perspective on intermediate severity stenoses.

Authors:  Yingwei Liu; Benjamin J W Chow; Girish Dwivedi
Journal:  Cardiovasc Diagn Ther       Date:  2015-02

Review 6.  A systematic review of imaging anatomy in predicting functional significance of coronary stenoses determined by fractional flow reserve.

Authors:  Miao Chu; Neng Dai; Junqing Yang; Jelmer Westra; Shengxian Tu
Journal:  Int J Cardiovasc Imaging       Date:  2017-03-06       Impact factor: 2.357

7.  Relative atherosclerotic plaque volume by CT coronary angiography trumps conventional stenosis assessment for identifying flow-limiting lesions.

Authors:  Nahoko Kato; Satoru Kishi; Armin Arbab-Zadeh; Frank J Rybicki; Shuzou Tanimoto; Jiro Aoki; Mika Watanabe; Yu Horiuchi; Koichi Furui; Kazuhiro Hara; Kenji Ibukuro; Joao A C Lima; Kengo Tanabe
Journal:  Int J Cardiovasc Imaging       Date:  2017-06-08       Impact factor: 2.357

Review 8.  Impact of plaque characteristics on the degree of functional stenosis.

Authors:  Pedro de Araújo Gonçalves; Alexandre Hideo-Kajita; Hector Manuel Garcia-Garcia
Journal:  Cardiovasc Diagn Ther       Date:  2017-04

Review 9.  Imaging the myocardial ischemic cascade.

Authors:  Arthur E Stillman; Matthijs Oudkerk; David A Bluemke; Menko Jan de Boer; Jens Bremerich; Ernest V Garcia; Matthias Gutberlet; Pim van der Harst; W Gregory Hundley; Michael Jerosch-Herold; Dirkjan Kuijpers; Raymond Y Kwong; Eike Nagel; Stamatios Lerakis; John Oshinski; Jean-François Paul; Riemer H J A Slart; Vinod Thourani; Rozemarijn Vliegenthart; Bernd J Wintersperger
Journal:  Int J Cardiovasc Imaging       Date:  2018-03-19       Impact factor: 2.357

10.  Relationship between coronary calcium score and high-risk plaque/significant stenosis.

Authors:  Kohichiro Iwasaki; Takeshi Matsumoto
Journal:  World J Cardiol       Date:  2016-08-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.